OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid TumorsMartin Gutierrez, Ignacio Melero|Clinical Cancer Research|2020Cited by 109
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0